Showing results (461-470 of 976) with videos related to

Sort By:
Pageof 98
Pediatric Pulmonology|July 11, 2012
Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasiaJoseph M Collaco, Lewis H Romer, Bridget D Stuart, et al.
PNAS Nexus|January 30, 2023
Mosquito tagging using DNA-barcoded nanoporous protein microcrystalsJulius D Stuart, Daniel A Hartman, Lyndsey I Gray, et al.
Plos Pathogens|November 8, 2012
Identification of a novel splice variant form of the influenza A virus M2 ion channel with an antigenically distinct ectodomainHelen M Wise, Edward C Hutchinson, Brett W Jagger, et al.
Plos One|October 14, 2015
Reef Fishes at All Trophic Levels Respond Positively to Effective Marine Protected AreasGerman A Soler, Graham J Edgar, Russell J Thomson, et al.
The Journal of Infectious Diseases|April 12, 2026
A first-in-human phase 1 clinical study in healthy volunteers to assess the safety, tolerability and pharmacokinetics of EDI048, a novel promising agent to treat enteric cryptosporidiosisMonish Jain, Kristen Stevenson, Anais Cheblal, et al.
The Journal of Infectious Diseases|May 27, 2026
Development of a Phase 1 Cryptosporidiosis Controlled Human Challenge Model in Healthy Volunteers Using Current Good Manufacturing Practice Cryptosporidium Parvum Oocysts and Conducted Under an Investigational New Drug ApplicationBridget D Stuart, Kristen Stevenson, Hanns-Christian Tillmann, et al.
Medical Microbiology and Immunology|January 5, 2002
The Leishmania genome project: new insights into gene organization and functionP J Myler, S M Beverley, A K Cruz, et al.
The Review of Scientific Instruments|June 27, 2024
Toward an integrated multi-gigahertz ionizing particle diagnosticJ Bohon, C Grace, M Gulley, et al.
The Lancet. Respiratory Medicine|June 21, 2014
Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validationBridget D Stuart, Joyce S Lee, Julia Kozlitina, et al.
Cancer Discovery|August 25, 2023
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant XenograftsLeonard Buckbinder, David J St Jean, Trang Tieu, et al.
Pageof 98